A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

NCT06295679

Status	RECRUITING
Sponsor	Amgen
Enrollment	7,000 participants

Key Eligibility Criteria

Inclusion (14)

- Adult participants e 18 years of age.
- Participants or participant's legally authorized representative has provided informed consent to participate in this study.
- Participants who meet one of the following:
- Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.
- OR

... and 9 more (see full listing online)

Exclusion (6)

- Stroke within past 1 month.
- Known hemorrhagic stroke at any time.
- Stroke due to thromboembolic event.
- Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment.
- Participants currently enrolled in another study involving any investigational procedure, device or drug.

... and 1 more (see full listing online)

Locations (90 total)

China Japan Friendship Hospital, Beijing, Beijing Municipality, China
Peking University First Hospital, Beijing, Beijing Municipality, China
Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
... and 87 more locations

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.